Ming Fai Industrial, a Shenzhen device maker, lacked validation and acceptance-status controls for ultrasound gel and probe covers.
What happened
FDA inspected the Shenzhen facility from March 06, 2023, through March 10, 2023, and found the ultrasound gel and probe cover devices adulterated because manufacturing did not conform to the Quality System regulation (the FDA’s CGMP rules for devices, 21 CFR Part 820). FDA cited missing validation documentation for ethylene oxide (EO) sterilization of a probe cover kit with a sterile gel pouch, for formulation calculation software, and for cleaning the ultrasound gel mixing tank. FDA also found in-process product pallets stored next to finished sterile product without clear acceptance or sterility status; the firm’s March 23, 2023 response was not adequate.
What FDA found
The firm lacked validation records for ethylene oxide sterilization of the probe cover kit containing a sterile gel pouch and did not justify using C-Arm Drape validation as representative.
21 CFR 820.75(a)The firm lacked validation records for the software used to calculate amounts of ingredients for the ultrasound gel formulation.
21 CFR 820.75(a)The firm lacked cleaning validation documentation for the mixing tank used to manufacture ultrasound gel.
21 CFR 820.75(a)In-process product pallets were held next to finished sterile product, and the product’s sterility and acceptance status were not clearly identified.
21 CFR 820.86
What FDA wants
FDA tells the firm to notify the office in writing within 15 business days of steps taken and corrective actions to address the violations and prevent recurrence, with a timetable for any delayed actions and English translations of non-English documents.
Who should pay attention
- device brands that buy ultrasound gel or probe covers from this manufacturer
- contract manufacturers of sterile gel or probe cover kits
- quality teams managing supplier validation and sterilization records
This is a summary. Read the original letter on fda.gov.